{"id":6100,"text":"Fimasartan, amlodipine, and hydrochlorothiazide are commonly used in combination therapies as antihypertensive drugs.","label":[[0,10,"Drug"],[12,22,"Drug"],[28,47,"Drug"],[94,116,"Drug"]],"Comments":[]}
{"id":6101,"text":"This study aimed to develop and validate an analytical method for fimasartan, its active and major metabolite fimasartan-amide, amlodipine, and hydrochlorothiazide in rat plasma using liquid chromatography-tandem mass spectrometry (LC-MS\/MS).","label":[[66,76,"Drug"],[110,126,"Drug"],[128,138,"Drug"],[144,163,"Drug"]],"Comments":[]}
{"id":6102,"text":"The standard calibration curves for fimasartan (1–500 ng\/mL), its active and major metabolite fimasartan-amide (0.3–100 ng\/mL), amlodipine (0.5–200 ng\/mL), and hydrochlorothiazide (5–5000 ng\/mL) were linear with R For the management of hypertension, approximately 70% of patients with hypertension take two or more antihypertensive drugs for effective blood pressure control.","label":[[36,46,"Drug"],[94,110,"Drug"],[128,138,"Drug"],[160,179,"Drug"],[236,248,"Pathology"],[285,297,"Pathology"],[315,337,"Drug"],[352,366,"Parameter"]],"Comments":[]}
{"id":6103,"text":"Among these combination drugs, calcium channel blockers, angiotensin II receptor antagonists, and thiazide diuretics are the most commonly used [1].","label":[[31,55,"Drug"],[57,92,"Drug"],[98,116,"Drug"]],"Comments":[]}
{"id":6104,"text":"Fimasartan is an angiotensin II receptor antagonist that has been approved in Korea and several Latin American countries for the treatment of mild-to-moderate hypertension.","label":[[0,51,"Drug"],[142,171,"Pathology"]],"Comments":[]}
{"id":6105,"text":"It has often been prescribed in combination with amlodipine and\/or hydrochlorothiazide in patients with hypertension, as these combination therapies exhibit additive effects [2,3,4].","label":[[49,59,"Drug"],[67,86,"Drug"],[104,116,"Pathology"]],"Comments":[]}
{"id":6106,"text":"In addition, fimasartan-amlodipine combination has led to similar adverse events compared with either monotherapy and resulted in a high compliance rate (>90%).","label":[[13,23,"Drug"],[24,34,"Drug"],[66,80,"Pathology"]],"Comments":[]}
{"id":6107,"text":"Based on these advantages, fimasartan is increasingly used in multiple combination therapies [4].","label":[[27,37,"Drug"]],"Comments":[]}
{"id":6108,"text":"The combined use of drugs with different mechanisms of action may provide advantages in terms of efficacy and tolerability; however, it also increases the possibility of drug–drug interactions (DDIs).","label":[],"Comments":[]}
{"id":6109,"text":"Therefore, the tolerability and safety of combination drugs were evaluated in the context of their DDI potential.","label":[],"Comments":[]}
{"id":6110,"text":"Co-administration of fimasartan and amlodipine did not result in substantial changes in the pharmacokinetics of either drug after multiple oral doses [3].","label":[[21,31,"Drug"],[36,46,"Drug"]],"Comments":[]}
{"id":6111,"text":"Similarly, no clinically relevant DDIs have been reported for the combination of fimasartan and hydrochlorothiazide, although fimasartan has a slight potential to increase the urinary excretion of hydrochlorothiazide [5].","label":[[81,91,"Drug"],[96,115,"Drug"],[126,136,"Drug"],[176,193,"Parameter"],[197,216,"Drug"]],"Comments":[]}
{"id":6112,"text":"A fixed-dose triple combination of fimasartan\/amlodipine\/hydrochlorothiazide 60\/10\/25 mg exhibited pharmacokinetic profiles similar to those of the corresponding doses of the three drugs [6].","label":[[35,45,"Drug"],[46,56,"Drug"],[57,76,"Drug"],[77,88,"Amount"]],"Comments":[]}
{"id":6113,"text":"In addition, a physiologically based pharmacokinetic (PBPK) model for fimasartan, amlodipine, and hydrochlorothiazide was developed by Rhee et al., and they predicted no remarkable DDIs using this PBPK model when fimasartan (120–240 mg) was co-administered with amlodipine (10 mg) and hydrochlorothiazide (25 mg), which is consistent with the observed clinical data [1].","label":[[70,80,"Drug"],[82,92,"Drug"],[98,117,"Drug"],[213,223,"Drug"],[225,235,"Amount"],[262,272,"Drug"],[274,279,"Amount"],[285,304,"Drug"],[306,311,"Amount"]],"Comments":[]}
{"id":6114,"text":"In addition to combination therapy, the use of herbal supplements is continuously increasing.","label":[],"Comments":[]}
{"id":6115,"text":"Recent studies disclosed that approximately 76% and 60% of adults in the USA and Europe, respectively, consume herbal supplements, and 25% of the herbal-drug consumers also take prescribed drugs [7,8], which increases the possibility of herb–drug interactions and may trigger the adverse effects of antihypertensive drugs.","label":[[280,295,"Pathology"],[299,321,"Drug"]],"Comments":[]}
{"id":6116,"text":"Adverse events of fimasartan were reported in 2.35% of patients.","label":[[0,14,"Pathology"],[18,28,"Drug"]],"Comments":[]}
{"id":6117,"text":"The most frequent events were dizziness (1.55%), headache (0.52%), abdominal pain, nausea, diarrhea, and coughing [9].","label":[[30,39,"Pathology"],[49,57,"Pathology"],[67,81,"Pathology"],[83,89,"Pathology"],[91,99,"Pathology"],[105,113,"Pathology"]],"Comments":[]}
{"id":6118,"text":"One case of angioedema was reported in 14,571 patients [9].","label":[[12,22,"Pathology"]],"Comments":[]}
{"id":6119,"text":"In addition, a case report described a 73-year-old patient with fimasartan-induced liver injury.","label":[[13,26,"Study"],[39,50,"Age"],[64,74,"Drug"],[83,95,"Pathology"]],"Comments":[]}
{"id":6120,"text":"Liver biopsy revealed hepatocellular necrosis and it was scored as a highly probable drug-induced liver injury [10,11].","label":[[22,45,"Pathology"],[98,110,"Pathology"]],"Comments":[]}
{"id":6121,"text":"Recently, an outcome study was conducted to evaluate the effects of early BP control and correction of metabolic abnormalities on future cardiovascular outcomes, relative to low-risk hypertension.","label":[[183,195,"Pathology"]],"Comments":[]}
{"id":6122,"text":"Fimasartan reduced pulse pressure—a predictor of cardiovascular events—in the elderly (by −8.2 ± 0.3 mmHg) and nonelderly (by −7.0 ± 0.2 mmHg) (p < 0.0001), after adjusting for confounding factors, which indicates a higher efficacy in the elderly than that in the nonelderly [12,13].","label":[[0,10,"Drug"],[19,33,"Parameter"],[49,70,"Pathology"]],"Comments":[]}
{"id":6123,"text":"Moreover, in a clinical study, “FANTASTIC”, to evaluate the rate of change in albuminuria in patients with diabetic chronic kidney disease, treatment with fimasartan for 6 months reduced albuminuria by more than 30%, which is expected to lower the risk of chronic kidney disease progression (compared with losartan).","label":[[15,29,"Study"],[78,89,"Parameter"],[107,138,"Pathology"],[155,165,"Drug"],[166,178,"Duration"],[187,198,"Parameter"],[256,279,"Pathology"],[306,314,"Drug"]],"Comments":[]}
{"id":6124,"text":"Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14].","label":[[34,44,"Drug"],[82,94,"Pathology"],[99,121,"Pathology"]],"Comments":[]}
{"id":6125,"text":"The rapidly growing fimasartan market and combination trends may increase the risk of developing DDIs.","label":[[20,30,"Drug"]],"Comments":[]}
{"id":6126,"text":"Therefore, we aimed to develop sensitive and simple analytical methods to monitor the pharmacokinetic features of fimasartan, amlodipine, and hydrochlorothisazide, the most frequently prescribed combination.","label":[[114,124,"Drug"],[126,136,"Drug"],[142,162,"Drug"]],"Comments":[]}
{"id":6127,"text":"In addition, to understand the effect of fimasartan metabolism, we included an analytical method for the major and active metabolite of fimasartan, fimasartan-amide (oxidative desulfuration or BR-A-557, Figure 1) [15].","label":[[41,51,"Drug"],[136,146,"Drug"],[148,164,"Drug"]],"Comments":[]}
{"id":6128,"text":"Red ginseng extract (RGE)—one of the most popular herbal medicines in many countries—has been reported for its anti-cancer, anti-diabetes, anti-inflammation, anti-oxidation, and liver protective effects.","label":[[0,25,"Herb name"]],"Comments":[]}
{"id":6129,"text":"It also has adaptogenic effects in the modulation of immune function and cardiovascular functions [16,17,18].","label":[],"Comments":[]}
{"id":6130,"text":"Ginsenosides are responsible for the therapeutic efficacy of RGE [19,20,21] and, therefore, individual ginsenosides such as Rg3, compound K, protopanax diol, and protopanaxatriol and ginseng products have been under clinical evaluation or drug development process [7,16].","label":[[0,12,"Herb name"],[61,64,"Herb name"],[103,115,"Herb name"],[124,127,"Herb name"],[129,139,"Herb name"],[141,156,"Herb name"],[162,178,"Herb name"],[183,190,"Herb name"],[216,235,"Study"]],"Comments":[]}
{"id":6131,"text":"A meta-analysis [22,23,24] of the effect of RGE on the anti-hypertensive effect in five randomized clinical trials revealed significant acute effects of Korean red ginseng on systolic or diastolic blood pressure at 2–3 h, but failed to show long-term effects [25].","label":[[0,15,"Study"],[44,47,"Herb name"],[88,123,"Study"],[153,159,"Ethnic group"],[153,171,"Herb name"],[175,211,"Parameter"]],"Comments":[]}
{"id":6132,"text":"Rg3-enriched Korean ginseng products have shown remarkable anti-hypertensive effects in spontaneously hypertensive rats [26,27].","label":[[0,27,"Herb name"],[102,114,"Pathology"]],"Comments":[]}
{"id":6133,"text":"Co-administration of Rg3-enriched Korean ginseng and American ginseng was effective at reducing blood pressure, and favorable cardiometabolic outcomes were observed in 80 patients with type-2 diabetes (HbA1c: 6.5–8%) and hypertension (systolic BP: 140–160 mmHg) [28].","label":[[21,48,"Herb name"],[34,40,"Ethnic group"],[53,61,"Ethnic group"],[53,69,"Herb name"],[96,110,"Parameter"],[168,179,"Cohort"],[185,200,"Pathology"],[202,207,"Parameter"],[209,215,"Amount"],[221,233,"Pathology"],[235,246,"Parameter"],[248,260,"Amount"]],"Comments":[]}
{"id":6134,"text":"In addition to the beneficial effect of ginseng products with respect to the anti-hypertensive effect, the drug–drug interaction potential between ginseng and anti-hypertensive drugs needs to be evaluated as combination therapy with drugs having different modes of action is often prescribed, especially as therapeutic drugs are taken along with health supplements.","label":[[40,47,"Herb name"],[147,154,"Herb name"],[159,182,"Drug"]],"Comments":[]}
{"id":6135,"text":"Therefore, we aimed to investigate the pharmacokinetic interactions between RGE—an extract from dried root of ginseng of 6 years and more than 60% of dried ginseng content—and a triple anti-hypertensive drug combination (fimasartan, amlodipine, and hydrochlorothiazide) in rats.","label":[[76,79,"Herb name"],[96,106,"Herb part"],[110,117,"Herb name"],[156,163,"Herb name"],[221,231,"Drug"],[233,243,"Drug"],[249,268,"Drug"]],"Comments":[]}
{"id":6136,"text":"RGE—an extract from dried root of ginseng of 6 years and more than 60% of dried ginseng content, 13.2 mg marker ginsenosides (GRb1 + GRg1 + GRg3), and 34.7 mg total ginsenosides per gram extract—was purchased from the Punggi Ginseng Cooperative Association (Youngjoo, Kyungpook, Korea) [29,30,31,32].","label":[[0,3,"Herb name"],[20,30,"Herb part"],[34,41,"Herb name"],[74,79,"Extraction process"],[80,87,"Herb name"],[97,104,"Amount"],[112,124,"Herb name"],[126,130,"Herb name"],[133,137,"Herb name"],[140,144,"Herb name"],[151,158,"Amount"],[165,177,"Herb name"]],"Comments":[]}
{"id":6137,"text":"Amlodipine besylate, hydrochlorothiazide, and berberine hydrochloride (IS) were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA).","label":[[0,19,"Drug"],[21,40,"Drug"]],"Comments":[]}
{"id":6138,"text":"Fimasartan potassium trihydrate (fimasartan) and the oxidized desulfurized metabolite of fimasartan (fimasartan-amide) were obtained from Boryung Pharm.","label":[[0,44,"Drug"],[53,118,"Drug"]],"Comments":[]}
{"id":6139,"text":"Co. Ltd. (Seoul, Korea).","label":[],"Comments":[]}
{"id":6140,"text":"All other chemicals and solvents were of reagent or analytical grade.","label":[],"Comments":[]}
{"id":6141,"text":"Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS\/MS system (Agilent, Wilmington, DE, USA).","label":[[0,10,"Drug"],[12,28,"Drug"],[30,40,"Drug"],[46,65,"Drug"]],"Comments":[]}
{"id":6142,"text":"An isocratic mobile phase, which consisted of a mixture of water and acetonitrile (30:70, v\/v) and contained 0.1% formic acid, was used at a flow rate of 0.20 mL\/min to elute the analytes from the rat plasma matrix.","label":[],"Comments":[]}
{"id":6143,"text":"Separation was performed using a Synergi Polar RP column (150 × 4.6 mm, 4 μm particle size; Pheonomenex, Torrance, CA, USA).","label":[],"Comments":[]}
{"id":6144,"text":"The analytes were monitored using multiple reaction monitoring (MRM) mode, and the optimized mass conditions are listed in Table 1.","label":[],"Comments":[]}
{"id":6145,"text":"Before starting sample analysis, the simultaneous analytical method was validated by evaluating the selectivity, linearity, accuracy, precision, recovery, and matrix effect.","label":[],"Comments":[]}
{"id":6146,"text":"Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves.","label":[],"Comments":[]}
{"id":6147,"text":"Calibration curves for a mixture of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide were prepared using the internal standard method.","label":[[36,46,"Drug"],[48,64,"Drug"],[66,76,"Drug"],[82,101,"Drug"]],"Comments":[]}
{"id":6148,"text":"Briefly, aliquots (50 μL in acetonitrile) of seven different concentrations of the standard curve mixture that contained fimasartan (1, 2, 5, 20, 50, 200, and 500 ng\/mL), fimasartan-amide (final concentrations of 0.3, 1, 2, 5, 20, 50, and 100 ng\/mL), amlodipine (0.5, 2, 5, 20, 50, 100, and 200 ng\/mL), and hydrochlorothiazide (5, 20, 50, 200, 500, 2000, and 5000 ng\/mL) were dried under gentle nitrogen gas stream and reconstituted with 50 μL rat blank plasma.","label":[[121,131,"Drug"],[171,187,"Drug"],[251,261,"Drug"],[307,326,"Drug"]],"Comments":[]}
{"id":6149,"text":"Then, 150 μL acetonitrile containing 1 ng\/mL berberine (IS) was added to the reconstituted standard curves.","label":[],"Comments":[]}
{"id":6150,"text":"After vortexing for 10 min and centrifuging for 10 min at 16,000× g, an aliquot (15 μL) of the supernatant was injected into the LC-MS\/MS system.","label":[],"Comments":[]}
{"id":6151,"text":"The linearity of the calibration standard was calculated from the peak height ratio of the analytes to the IS using the weight-adjusted method (1\/x The precision and accuracy of the inter- and intra-day assays were assessed by five or six measurements of three QC samples of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide.","label":[[275,285,"Drug"],[287,303,"Drug"],[305,315,"Drug"],[321,340,"Drug"]],"Comments":[]}
{"id":6152,"text":"Precision was evaluated using the coefficient of variation (CV, %) of five or six QC sample measurements.","label":[],"Comments":[]}
{"id":6153,"text":"Accuracy was calculated by dividing the measured QC concentration by the spiked QC concentration.","label":[],"Comments":[]}
{"id":6154,"text":"Extraction recovery was calculated by comparing the peak areas of the three QC samples in the pre-extraction samples with those of the post-extraction blank plasma spiked with the corresponding QC samples.","label":[],"Comments":[]}
{"id":6155,"text":"Matrix effects were determined by comparing the peak area obtained from the post-extraction blank plasma spiked with three QC concentrations of the mixture of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide and the peak area from the corresponding concentration of the blank solution.","label":[[159,169,"Drug"],[171,187,"Drug"],[189,199,"Drug"],[205,224,"Drug"]],"Comments":[]}
{"id":6156,"text":"The stabilities of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide in rat plasma were tested under various conditions.","label":[[19,29,"Drug"],[31,47,"Drug"],[49,59,"Drug"],[65,84,"Drug"]],"Comments":[]}
{"id":6157,"text":"Bench-top stability was calculated by comparing QC samples stored for 12 h at 25 °C with the untreated QC samples.","label":[],"Comments":[]}
{"id":6158,"text":"For freeze–thaw stability, QC samples were analyzed after three freeze–thaw cycles.","label":[],"Comments":[]}
{"id":6159,"text":"One cycle of the freeze–thaw process involved storing the QC samples at −80 °C for >12 h and thawing at 25 °C for 6 h. After three freeze–thaw cycles, the concentrations of the QC samples were determined using freshly prepared calibration standards.","label":[],"Comments":[]}
{"id":6160,"text":"Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 °C for 24 h (compared with the untreated QC samples).","label":[],"Comments":[]}
{"id":6161,"text":"Male Sprague-Dawley rats aged seven weeks (Samtako, Osan, Korea) were acclimatized for one week in an animal facility at Kyungpook National University.","label":[[0,4,"Sex"]],"Comments":[]}
{"id":6162,"text":"Food and water were provided ad libitum.","label":[],"Comments":[]}
{"id":6163,"text":"All animal experiments were approved by the Institutional Animal Care and Use Committee of Kyungpook National University (approval no.","label":[],"Comments":[]}
{"id":6164,"text":"KNU 2017-0044).","label":[],"Comments":[]}
{"id":6165,"text":"To investigate the DDIs among fimasartan, amlodipine, and hydrochlorothiazide, rats were randomly divided into a combination group (n = 6) and a single group (n = 6, for individual drug administration).","label":[[30,40,"Drug"],[42,52,"Drug"],[58,77,"Drug"]],"Comments":[]}
{"id":6166,"text":"The femoral arteries and veins of the rats were cannulated with PE50 polyethylene tubing (Jungdo, Seoul, Korea) under anesthesia with zoletil and lompun (50 and 5 mg\/kg, respectively, intramuscular injection), and heparinized saline (10 U\/mL) was used to prevent blood clotting.","label":[],"Comments":[]}
{"id":6167,"text":"Pharmacokinetic studies were initiated after recovery from anesthesia.","label":[],"Comments":[]}
{"id":6168,"text":"Each rat in the combination group received a mixture of fimasartan (3 mg\/kg), amlodipine (5 mg\/kg), and hydrochlorothiazide (5 mg\/kg) dissolved in saline containing 10% DMSO.","label":[[56,66,"Drug"],[68,75,"Amount"],[78,88,"Drug"],[90,97,"Amount"],[104,123,"Drug"],[125,132,"Amount"]],"Comments":[]}
{"id":6169,"text":"The rats in the single group orally received individual drug solutions at the same dose as present in the triple mixture solution.","label":[],"Comments":[]}
{"id":6170,"text":"Blood samples were collected through the femoral artery at 0, 0.25, 0.5, 1, 2, 4, 8, and 24 h following the oral administration of fimasartan, amlodipine, and hydrochlorothiazide.","label":[[131,141,"Drug"],[143,153,"Drug"],[159,178,"Drug"]],"Comments":[]}
{"id":6171,"text":"After centrifugation of the blood samples at 8000× g for 1 min, 50 μL aliquots of the plasma samples were stored at −80 °C until analysis.","label":[],"Comments":[]}
{"id":6172,"text":"Rats were randomly divided into three groups, i.e., control (n = 6, vehicle treatment), single (n = 6, 1.5 g\/kg), and multiple RGE treatments (n = 6, 1.5 g\/kg for 7 days).","label":[[103,111,"Amount"],[127,130,"Herb name"],[150,158,"Amount"],[159,169,"Duration"]],"Comments":[]}
{"id":6173,"text":"Importantly, rats in the multiple RGE group received RGE suspension (1.5 g\/kg\/3 mL\/day) for 7 days via oral gavage, while rats in the single RGE treatment group received water (3 mL\/kg) for 6 days via oral gavage and RGE suspension (1.5 g\/kg\/3 mL) via oral gavage on the day 7.","label":[[34,37,"Herb name"],[53,56,"Herb name"],[69,82,"Amount"],[88,98,"Duration"],[141,144,"Herb name"],[177,184,"Amount"],[186,196,"Duration"],[217,220,"Herb name"],[233,246,"Amount"]],"Comments":[]}
{"id":6174,"text":"The control group received water (3 mL\/kg) for seven days by oral gavage.","label":[[34,41,"Amount"],[43,57,"Duration"]],"Comments":[]}
{"id":6175,"text":"One hour after the last RGE treatment, rats received a mixture of fimasartan, amlodipine, and hydrochlorothiazide at doses of 3, 5, and 5 mg\/kg, respectively, by oral gavage.","label":[[24,27,"Herb name"],[66,76,"Drug"],[78,88,"Drug"],[94,113,"Drug"],[126,143,"Amount"]],"Comments":[]}
{"id":6176,"text":"Subsequently, blood samples were collected via the femoral artery at 0, 0.25, 0.5, 1, 2, 4, 8, and 24 h. After centrifugation of the blood samples at 8000× g for 1 min, 50 μL aliquots of the plasma samples were stored at −80 °C until analysis.","label":[],"Comments":[]}
{"id":6177,"text":"Plasma samples (50 μL) were then mixed with 150 μL acetonitrile containing 1 ng\/mL berberine (IS).","label":[],"Comments":[]}
{"id":6178,"text":"After vortexing for 10 min and centrifuging for 10 min at 16,000× g, an aliquot (15 μL) of the supernatant was injected into the LC-MS\/MS system.","label":[],"Comments":[]}
{"id":6179,"text":"Randomly divided rats received vehicle (control group, n = 4), single (1.5 g\/kg, n = 4), or multiple RGE treatments (1.5 g\/kg for 7 days, n = 4).","label":[[71,79,"Amount"],[101,104,"Herb name"],[117,125,"Amount"],[126,136,"Duration"]],"Comments":[]}
{"id":6180,"text":"The procedure was the same as described previously.","label":[],"Comments":[]}
{"id":6181,"text":"The jejunal segments were then isolated and rinsed using pre-warmed saline.","label":[],"Comments":[]}
{"id":6182,"text":"Subsequently, they were mounted in the tissue holder of a Navicyte easy mount Ussing chamber (Warner Instruments, Holliston, MA, USA) and acclimated in Hank’s balanced salt solution (HBSS, pH 7.4) for 15 min with continuous oxygenation (95% O₂\/5% CO₂).","label":[],"Comments":[]}
{"id":6183,"text":"An intestinal permeability study was performed by adding 1 mL HBSS containing fimasartan, amlodipine, or hydrochlorothiazide (10 μM each) on the donor side and 1 mL fresh HBSS on the receiver side.","label":[[78,88,"Drug"],[90,100,"Drug"],[105,124,"Drug"]],"Comments":[]}
{"id":6184,"text":"Then, a 400 μL aliquot was withdrawn from the receiver side every 30 min for 2 h, and an equal volume of pre-warmed fresh HBSS was added to replenish the lost volume.","label":[],"Comments":[]}
{"id":6185,"text":"For amlodipine analysis, 50 μL aliquots were mixed with 150 μL acetonitrile containing 1 ng\/mL berberine (IS).","label":[[4,14,"Drug"]],"Comments":[]}
{"id":6186,"text":"After vortexing for 10 min and centrifuging for 10 min at 16,000× g, an aliquot (15 μL) of the supernatant was injected into the LC-MS\/MS system.","label":[],"Comments":[]}
{"id":6187,"text":"Pharmacokinetic parameters were calculated using non-compartmental analyses and compared using the Kruskal–Wallis test.","label":[],"Comments":[]}
{"id":6188,"text":"p < 0.05 was considered significant.","label":[],"Comments":[]}
{"id":6189,"text":"To optimize the electrospray ionization conditions for fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide, each compound was directly injected into the mass spectrometer ionization source.","label":[[55,65,"Drug"],[67,83,"Drug"],[85,95,"Drug"],[101,120,"Drug"]],"Comments":[]}
{"id":6190,"text":"The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1).","label":[],"Comments":[]}
{"id":6191,"text":"Fimasartan, fimasartan-amide, and amlodipine had optimal ionization in the positive mode, whereas hydrochlorothiazide showed optimal ionization in the negative mode (Table 1).","label":[[0,10,"Drug"],[12,28,"Drug"],[34,44,"Drug"],[98,117,"Drug"]],"Comments":[]}
{"id":6192,"text":"Optimized MRM transitions and MS\/MS conditions for the analytes are listed in Table 1 and Figure 1, respectively.","label":[],"Comments":[]}
{"id":6193,"text":"These conditions were consistent with those presented in previous reports [15,33,34,35,36].","label":[],"Comments":[]}
{"id":6194,"text":"Selectivity was confirmed in male Sprague-Dawley rat plasma of eight different origins and was assessed by comparing the blank plasma peak response with that of plasma spiked with the lower limit of quantification (LLOQ) of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide (Table 1).","label":[[29,33,"Sex"],[224,234,"Drug"],[236,252,"Drug"],[254,264,"Drug"],[270,289,"Drug"]],"Comments":[]}
{"id":6195,"text":"The signal-to-noise ratios of each analyte of the LLOQ were all over 10.","label":[],"Comments":[]}
{"id":6196,"text":"Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide.","label":[[66,76,"Drug"],[78,94,"Drug"],[96,106,"Drug"],[112,131,"Drug"],[206,216,"Drug"],[218,228,"Drug"],[234,253,"Drug"]],"Comments":[]}
{"id":6197,"text":"The peak retention times for fimasartan, fimasartan-amide, amlodipine, hydrochlorothiazide, and the IS were 3.1, 2.7, 3.2, 2.2, and 4.6 min, respectively.","label":[[29,39,"Drug"],[41,57,"Drug"],[59,69,"Drug"],[71,90,"Drug"]],"Comments":[]}
{"id":6198,"text":"The results showed no disturbance peaks derived from rat blank plasma at the retention times of fimasartan, fimasartan-amide, amlodipine, hydrochlorothiazide, and IS under our MS\/MS analysis conditions (Figure 2).","label":[[96,106,"Drug"],[108,124,"Drug"],[126,136,"Drug"],[138,157,"Drug"]],"Comments":[]}
{"id":6199,"text":"Linearity was evaluated using calibration curves of the mixture of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide (Table 1).","label":[[67,77,"Drug"],[79,95,"Drug"],[97,107,"Drug"],[113,132,"Drug"]],"Comments":[]}
{"id":6200,"text":"The calibration curves showed good linearity in the ranges 1–500 ng\/mL (for fimasartan), 0.3–100 ng\/mL (for fimasartan-amide), 0.5–200 ng\/mL (for amlodipine), and 5–5000 ng\/mL (for hydrochlorothiazide), with a correlation coefficient (R Table 2 summarizes the intra- and inter-day precision and accuracy of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide.","label":[[76,86,"Drug"],[108,124,"Drug"],[146,156,"Drug"],[181,200,"Drug"],[307,317,"Drug"],[319,335,"Drug"],[337,347,"Drug"],[353,372,"Drug"]],"Comments":[]}
{"id":6201,"text":"Precision was assessed as CV (%) for all analytes and the values were in the range of 2.38–6.77% in the intra-day batch and 1.96–7.75% in the inter-day batch.","label":[],"Comments":[]}
{"id":6202,"text":"Accuracy is expressed as a percentage (%) of the concentrations determined from the calibration curve over the nominal concentrations.","label":[],"Comments":[]}
{"id":6203,"text":"The accuracy of all analytes was in the range of 87.94–109.6% in the intra-day batch and 98.15–107.2% in the inter-day batch.","label":[],"Comments":[]}
{"id":6204,"text":"The accuracy of the QC sample was obtained through back calculations from the equations of the standard curve.","label":[],"Comments":[]}
{"id":6205,"text":"Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37].","label":[],"Comments":[]}
{"id":6206,"text":"Table 3 summarizes the extraction recoveries and matrix effects.","label":[],"Comments":[]}
{"id":6207,"text":"The extraction recoveries for fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide were high and reproducible in the range of extraction recovery (75.92–96.73%) and CV (4.14–13.4%).","label":[[30,40,"Drug"],[42,58,"Drug"],[60,70,"Drug"],[76,95,"Drug"]],"Comments":[]}
{"id":6208,"text":"Therefore, the protein precipitation method—employing three volumes of acetonitrile—utilized in this study could efficiently extract fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide from rat plasma.","label":[[133,143,"Drug"],[145,161,"Drug"],[163,173,"Drug"],[179,198,"Drug"]],"Comments":[]}
{"id":6209,"text":"The matrix effects ranged from 34.11% to 37.08% with a CV range of 9.44–13.6% for fimasartan, from 6.628% to 8.030% with a CV range of 8.90–10.9% for fimasartan-amide, from 39.87 to 49.35% with a CV range of 9.11–13.2% for amlodipine, and from 9.192% to 12.29% with a CV range of 6.73–11.1% for hydrochlorothiazide.","label":[[82,92,"Drug"],[150,166,"Drug"],[223,233,"Drug"],[295,314,"Drug"]],"Comments":[]}
{"id":6210,"text":"The results suggested that the co-eluting substances showed substantial matrix effects on the ionization of the analytes.","label":[],"Comments":[]}
{"id":6211,"text":"However, the matrix effects were stable for the three QC concentrations in the six samples of each plasma matrix.","label":[],"Comments":[]}
{"id":6212,"text":"Therefore, we conclude that our sample preparation process can be used to analyze the concentrations of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide in rat plasma samples.","label":[[104,114,"Drug"],[116,132,"Drug"],[134,144,"Drug"],[150,169,"Drug"]],"Comments":[]}
{"id":6213,"text":"The extraction recovery and matrix effects of the IS were also high and reproducible (Table 3).","label":[],"Comments":[]}
{"id":6214,"text":"The results of the stability experiments are presented in Table 4.","label":[],"Comments":[]}
{"id":6215,"text":"The precision and accuracy for the bench-top stability, the post-preparative stability, and the three cycles of freeze–thaw stability were lower than 15%.","label":[],"Comments":[]}
{"id":6216,"text":"These results provide evidence that fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide in rat plasma samples were stable for up to 6 h at 25 °C (bench-top stability).","label":[[36,46,"Drug"],[48,64,"Drug"],[66,76,"Drug"],[82,101,"Drug"]],"Comments":[]}
{"id":6217,"text":"Moreover, they were stable for 24 h in the autosampler tray after sample treatment and remained stable for three freeze–thaw cycles.","label":[],"Comments":[]}
{"id":6218,"text":"First, we compared the pharmacokinetics of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide in rats, following their oral administration (as monotherapy or combination dose) (Figure 3).","label":[[43,53,"Drug"],[55,71,"Drug"],[73,83,"Drug"],[89,108,"Drug"]],"Comments":[]}
{"id":6219,"text":"The plasma concentration profiles of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide were very similar, regardless of whether these drugs were orally administered individually or simultaneously as combination doses (3, 5, and 5 mg\/kg for fimasartan, amlodipine, and hydrochlorothiazide, respectively).","label":[[37,47,"Drug"],[49,65,"Drug"],[67,77,"Drug"],[83,102,"Drug"],[234,251,"Amount"],[256,266,"Drug"],[268,278,"Drug"],[284,303,"Drug"]],"Comments":[]}
{"id":6220,"text":"Pharmacokinetic parameters, such as C To investigate the herb–drug interactions between RGE and the antihypertensive drugs, the pharmacokinetic parameters of fimasartan, amlodipine, and hydrochlorothiazide in control rats were compared with those in rats that were orally administered a single dose of RGE and multiple doses of RGE for one week (Figure 4 and Table 6).","label":[[88,91,"Herb name"],[100,122,"Drug"],[158,168,"Drug"],[170,180,"Drug"],[186,205,"Drug"],[302,305,"Herb name"],[328,331,"Herb name"],[332,344,"Duration"]],"Comments":[]}
{"id":6221,"text":"The plasma profile of fimasartan was similar, and pharmacokinetic parameters, such as C The T To investigate whether the decreased permeability caused by repeated RGE treatment was specific for amlodipine, we also measured the intestinal permeability of fimasartan and hydrochlorothiazide.","label":[[22,32,"Drug"],[163,166,"Herb name"],[194,204,"Drug"],[254,264,"Drug"],[269,288,"Drug"]],"Comments":[]}
{"id":6222,"text":"The P Fimasartan is effective at reducing blood pressure.","label":[[6,16,"Drug"],[42,56,"Parameter"]],"Comments":[]}
{"id":6223,"text":"In large clinical studies, fimasartan showed an excellent safety profile and, when combined with hydrochlorothiazide or amlodipine, it showed a better effect with respect to controlling blood pressure than that of monotherapy.","label":[[9,25,"Study"],[27,37,"Drug"],[97,116,"Drug"],[120,130,"Drug"],[186,200,"Parameter"]],"Comments":[]}
{"id":6224,"text":"It has beneficial effects with respect to protecting against major adverse cardiovascular events and its renoprotective effects in hypertensive diabetic chronic kidney disease are under evaluation [4,12,14,38].","label":[[67,96,"Pathology"],[131,175,"Pathology"]],"Comments":[]}
{"id":6225,"text":"Preclinical studies have demonstrated organ-protective effects of fimasartan [4].","label":[[0,19,"Study"],[66,76,"Drug"]],"Comments":[]}
{"id":6226,"text":"These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy.","label":[[27,37,"Drug"],[86,98,"Pathology"],[133,143,"Drug"]],"Comments":[]}
{"id":6227,"text":"Fimasartan and its combination drugs have been introduced into the market in form of the following formulations: Kanarb Jung et al.","label":[[0,10,"Drug"]],"Comments":[]}
{"id":6228,"text":"[6] investigated the pharmacokinetic interactions of triple combinations of fimasartan, amlodipine, and hydrochlorothiazide.","label":[[76,86,"Drug"],[88,98,"Drug"],[104,123,"Drug"]],"Comments":[]}
{"id":6229,"text":"For this, they applied two different sample preparation methods including protein precipitation for fimasartan\/amlodipine and liquid–liquid extraction for hydrochlorothiazide.","label":[[100,110,"Drug"],[111,121,"Drug"],[155,174,"Drug"]],"Comments":[]}
{"id":6230,"text":"In this study, we developed simple and simultaneous analytical method for fimasartan, fimasartan-amide (a major metabolite of fimasartan), amlodipine, and hydrochlorothiazide in rat plasma using the protein precipitation method; therefore, it has advantages of a simple sample pretreatment procedures and a shortened run time.","label":[[74,84,"Drug"],[86,137,"Drug"],[139,149,"Drug"],[155,174,"Drug"]],"Comments":[]}
{"id":6231,"text":"In addition, we included the analysis of a major active metabolite of fimasartan, fimasartan-amide, which is expected to be easily applied to efficacy and pharmacokinetic-pharmacodynamic studies of antihypertensive combination drugs as well.","label":[[43,98,"Drug"],[198,232,"Drug"]],"Comments":[]}
{"id":6232,"text":"Finally, to the best of our knowledge, this is the first validated report of an LC-MS\/MS method for the simple and simultaneous determination of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide from rat plasma.","label":[[145,155,"Drug"],[157,173,"Drug"],[175,185,"Drug"],[191,210,"Drug"]],"Comments":[]}
{"id":6233,"text":"A number of analytical methods for monitoring individual fimasartan, amlodipine, or hydrochlorothiazide in plasma samples using tandem mass did not use the quantitative and qualitative MRM trace.","label":[[57,67,"Drug"],[69,79,"Drug"],[84,103,"Drug"]],"Comments":[]}
{"id":6234,"text":"We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1).","label":[[114,124,"Drug"],[126,136,"Drug"],[142,161,"Drug"]],"Comments":[]}
{"id":6235,"text":"In addition, in a selectivity evaluation, we confirmed that there were no interfering peaks in the individual substance compared with all four substances spiked in blank rat plasma.","label":[],"Comments":[]}
{"id":6236,"text":"However, the use of two MRM traces would have increased the quality and usability of the analytical method, as it provides more certainty in identifying the analytes among the existing exogenous and endogenous structural analogues [41].","label":[],"Comments":[]}
{"id":6237,"text":"Therefore, it is necessary to apply and validate two MRM trace methods for fimasartan and fimasartan-amide, amlodipine, and hydrochlorothiazide in our future analysis.","label":[[75,85,"Drug"],[90,106,"Drug"],[108,118,"Drug"],[124,143,"Drug"]],"Comments":[]}
{"id":6238,"text":"We then applied our analytical method to evaluate the pharmacokinetic interactions among the triple combination of these drugs and the effect of RGE treatment on the same.","label":[[145,148,"Herb name"]],"Comments":[]}
{"id":6239,"text":"Pharmacokinetic interactions among the triple combination drugs were evaluated by comparing oral monotherapy of fimasartan, amlodipine, and hydrochlorothiazide, as well as the oral administration of the triple mixture with the corresponding dose.","label":[[112,122,"Drug"],[124,134,"Drug"],[140,159,"Drug"]],"Comments":[]}
{"id":6240,"text":"The results indicated no interaction in the pharmacokinetic parameters of the orally administered triple combination compared with those of the individual components (Figure 3 and Table 5).","label":[],"Comments":[]}
{"id":6241,"text":"When compared with the previous pharmacokinetic results of antihypertensive drugs, pharmacokinetic parameters such as C Next, we evaluated the interactions between RGE and the triple combination.","label":[[59,81,"Drug"],[164,167,"Herb name"]],"Comments":[]}
{"id":6242,"text":"No significant difference was observed in the pharmacokinetic parameters of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide (except for the T Our validated analytical method for fimasartan, its active metabolite fimasartan-amide, amlodipine, and hydrochlorothiazide can be easily extrapolated to pharmacokinetic, efficacy, and toxicokinetic studies.","label":[[76,86,"Drug"],[88,104,"Drug"],[106,116,"Drug"],[122,141,"Drug"],[196,206,"Drug"],[230,246,"Drug"],[248,258,"Drug"],[264,283,"Drug"],[345,366,"Study"]],"Comments":[]}
{"id":6243,"text":"In an application study, we successfully assessed the pharmacokinetic interactions between these triple combination drugs and co-administered drugs and herbal supplements.","label":[],"Comments":[]}
{"id":6244,"text":"In addition, repeated administration of RGE (1.5 g\/kg\/day) for one week delayed the absorption of amlodipine compared with single RGE administration (or the control group), but no interaction was detected between hydrochlorothiazide and fimasartan.","label":[[40,43,"Herb name"],[45,53,"Amount"],[53,57,"Frequency"],[59,71,"Duration"],[98,108,"Drug"],[130,133,"Herb name"],[213,232,"Drug"],[237,247,"Drug"]],"Comments":[]}
{"id":6245,"text":"In conclusion, using a triple combination of anti-hypertensive drugs and simultaneous analytical methods, we conducted efficient drug interaction and pharmacokinetic studies using fewer animals.","label":[[45,68,"Drug"],[150,173,"Study"]],"Comments":[]}
{"id":6246,"text":"Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.","label":[],"Comments":[]}
{"id":6247,"text":"Conceptualization, M.-K.C.","label":[],"Comments":[]}
{"id":6248,"text":"and I.-S.S.; methodology, S.-Y.J., J.-H.J.","label":[],"Comments":[]}
{"id":6249,"text":"and J.-H.P.","label":[],"Comments":[]}
{"id":6250,"text":"; validation, S.-Y.J., J.-H.J.","label":[],"Comments":[]}
{"id":6251,"text":"and J.-H.P.","label":[],"Comments":[]}
{"id":6252,"text":"; formal analysis, S.-Y.J.","label":[],"Comments":[]}
{"id":6253,"text":"and M.P.","label":[],"Comments":[]}
{"id":6254,"text":"; investigation, S.-Y.J., J.-H.J., J.-H.P., J.L.","label":[],"Comments":[]}
{"id":6255,"text":"and M.P.","label":[],"Comments":[]}
{"id":6256,"text":"; writing—original draft preparation, S.-Y.J., J.-H.J., J.-H.P., J.L.","label":[],"Comments":[]}
{"id":6257,"text":"and M.P.","label":[],"Comments":[]}
{"id":6258,"text":"; writing—review and editing, M.-K.C.","label":[],"Comments":[]}
{"id":6259,"text":"and I.-S.S.; supervision, M.-K.C.","label":[],"Comments":[]}
{"id":6260,"text":"and I.-S.S.; project administration, I.-S.S.; funding acquisition, I.-S.S. All authors have read and agreed to the published version of the manuscript.","label":[],"Comments":[]}
{"id":6261,"text":"The animal study protocol was approved by the Institutional Animal Care and Use Committee of Kyungpook National University (protocol code KNU 2017-0044 and date of approval 6 April 2017).","label":[[4,16,"Study"]],"Comments":[]}
{"id":6262,"text":"Not applicable.","label":[],"Comments":[]}
{"id":6263,"text":"Not applicable.","label":[],"Comments":[]}
{"id":6264,"text":"The authors declare no conflict of interest.","label":[],"Comments":[]}
{"id":6265,"text":"Structure and product ion mass spectra of (A) fimasartan, (B) fimasartan-amide, (C) amlodipine, and (D) hydrochlorothiazide.","label":[[46,56,"Drug"],[62,78,"Drug"],[84,94,"Drug"],[104,123,"Drug"]],"Comments":[]}
{"id":6266,"text":"Representative multiple reaction monitoring (MRM) chromatogram of fimasartan, fimasartan-amide, amlodipine, hydrochlorothiazide, and IS (berberine) in (A) blank rat plasma; (B) rat blank plasma spiked with standard solution at a lower limit of quantification (LLOQ); and (C) rat plasma samples at 1 h following oral administration of fimasartan, amlodipine, and hydrochlorothiazide.","label":[[66,76,"Drug"],[78,94,"Drug"],[96,106,"Drug"],[108,127,"Drug"],[334,344,"Drug"],[346,356,"Drug"],[362,381,"Drug"]],"Comments":[]}
{"id":6267,"text":"Plasma concentration–time profile of (A) fimasartan, (B) fimasartan-amide, (C) amlodipine, and (D) hydrochlorothiazide in rats that were orally administered a mixture of fimasartan (3 mg\/kg), amlodipine (5 mg\/kg), and hydrochlorothiazide (5 mg\/kg) (triple, ●) or a single component with the same dose (single, ○).","label":[[41,51,"Drug"],[57,73,"Drug"],[79,89,"Drug"],[99,118,"Drug"],[170,180,"Drug"],[182,189,"Amount"],[192,202,"Drug"],[204,211,"Amount"],[218,237,"Drug"],[239,246,"Amount"]],"Comments":[]}
{"id":6268,"text":"Data represent the mean ± standard deviation (n = 5).","label":[],"Comments":[]}
{"id":6269,"text":"Plasma concentration–time profile of (A) fimasartan, (B) fimasartan-amide, (C) amlodipine, and (D) hydrochlorothiazide in rats orally administered a mixture of fimasartan (3 mg\/kg), amlodipine (5 mg\/kg), and hydrochlorothiazide (5 mg\/kg) with vehicle (control group), single-dose RGE (1.5 g\/kg; RGE-SA) and repeated-dose RGE (1.5 g\/kg, once daily for one week; RGE-1WRA).","label":[[41,51,"Drug"],[57,73,"Drug"],[79,89,"Drug"],[99,118,"Drug"],[160,170,"Drug"],[172,179,"Amount"],[182,192,"Drug"],[194,201,"Amount"],[208,227,"Drug"],[229,236,"Amount"],[280,283,"Herb name"],[285,293,"Amount"],[295,298,"Herb name"],[299,301,"Frequency"],[321,324,"Herb name"],[326,334,"Amount"],[336,346,"Frequency"],[347,359,"Duration"],[361,364,"Herb name"]],"Comments":[]}
{"id":6270,"text":"Data represent the mean ± standard deviation (n = 5).","label":[],"Comments":[]}
{"id":6271,"text":"Comparison of (A) T MS\/MS parameters for the detection and standard calibration curves for fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide.","label":[[91,101,"Drug"],[103,119,"Drug"],[121,131,"Drug"],[137,156,"Drug"]],"Comments":[]}
{"id":6272,"text":"Intra- and inter-day precision and accuracy of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide.","label":[[47,57,"Drug"],[59,75,"Drug"],[77,87,"Drug"],[93,112,"Drug"]],"Comments":[]}
{"id":6273,"text":"Data represented as mean and CV from five or six independent experiments.","label":[],"Comments":[]}
{"id":6274,"text":"Extraction recoveries and matric effects for the determination of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide.","label":[[66,76,"Drug"],[78,94,"Drug"],[96,106,"Drug"],[112,131,"Drug"]],"Comments":[]}
{"id":6275,"text":"Data represented as mean and CV from six independent experiments.","label":[],"Comments":[]}
{"id":6276,"text":"Stability of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide.","label":[[13,23,"Drug"],[25,41,"Drug"],[43,53,"Drug"],[59,78,"Drug"]],"Comments":[]}
{"id":6277,"text":"Data represented as mean and CV from three independent experiments.","label":[],"Comments":[]}
{"id":6278,"text":"Pharmacokinetic parameters of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide in rats that were orally administered monotherapy or a combination of fimasartan (3 mg\/kg), amlodipine (5 mg\/kg), and hydrochlorothiazide (5 mg\/kg).","label":[[30,40,"Drug"],[42,58,"Drug"],[60,70,"Drug"],[76,95,"Drug"],[166,176,"Drug"],[178,185,"Amount"],[188,198,"Drug"],[200,207,"Amount"],[214,233,"Drug"],[235,242,"Amount"]],"Comments":[]}
{"id":6279,"text":"Data are represented as mean ± standard deviation from six rats; NC: not calculated; C Pharmacokinetic parameters of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide in rats orally administered a mixture of fimasartan (3 mg\/kg), amlodipine (5 mg\/kg), and hydrochlorothiazide (5 mg\/kg) with vehicle (control group), single-dose RGE (1.5 g\/kg; RGE-SA), and repeated-dose RGE (1.5 g\/kg, once daily for one week; RGE-1WRA).","label":[[55,63,"Cohort"],[117,127,"Drug"],[129,145,"Drug"],[147,157,"Drug"],[163,182,"Drug"],[224,234,"Drug"],[236,243,"Amount"],[246,256,"Drug"],[258,265,"Amount"],[272,291,"Drug"],[293,300,"Amount"],[332,343,"Frequency"],[344,347,"Target"],[349,357,"Amount"],[359,362,"Target"],[363,365,"Frequency"],[386,389,"Target"],[391,399,"Amount"],[401,411,"Frequency"],[412,424,"Duration"],[426,429,"Target"]],"Comments":[]}
{"id":6280,"text":"Data are represented as mean ± standard deviation from five rats; NC: not calculated; C","label":[],"Comments":[]}
